PepGen Inc.

NASDAQ:PEPG

Biotechnology

Healthcare
$3.83 +5.29%

+$0.09 today

Market cap
$265.27M
Beta
1.93
P/E (TTM)
-1.6
EPS (TTM)
-$1.12
52W Low $1.01High $7.80

Volume 3.39M

Average 1.37M

PEPG Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

PepGen Inc.NASDAQ: PEPG

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$319K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$1.72M.

Context

  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly gross profit holds near -$319K or moves back toward the trailing-twelve-month quarterly average of -$429K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$319K+69.8% QoQ
Last fiscal yearDec 2025
-$1.4M+7.2% YoY
LTMMar 2026
-$1.72M-351.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+7.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(1.4M) USD
Year-over-year change
+7.2%

Gross Profit vs competitors

How PEPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -351.6% is the lowest of 7, against a peer median of +69.4%.
PEPG Competitors
Gross Profit for PEPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$149K USD+99.1%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$289K USD+75.2%——
PEPGPepGen Inc.LTM Mar 2026-$1.72M USD-351.6%——
NKTXNkarta, Inc.LTM Mar 2026-$2.34M USD———
MOLNMolecular Partners AGLTM Mar 2026-CHF 2.61M CHF+91.8%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$11.06M USD-20.7%+15.4%2105.7%
ALECAlector, Inc.LTM Mar 2026-$11.28M USD-289.4%-56.0%61.2%
FATEFate Therapeutics, Inc.LTM Mar 2026-$26.26M USD+63.7%—415.8%
Peer median (excluding PEPG) —+69.4%-20.3%415.8%

Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue001.18M1.51M1.4M
Gross Profit00(1.18M)(1.51M)(1.4M)
Gross Margin—————
Research & Development23.8M54.08M68.13M76.48M71.04M
Selling, General & Admin8.11M14.22M16.64M21.26M22.57M
Operating Expenses27.11M68.3M83.58M96.23M92.22M
Depreciation & Amortization178K493K1.18M1.51M1.4M
EBITDA(27.1M)(64.91M)(77.37M)(89.09M)(88.21M)
EBITDA Margin—————
Operating Income(27.11M)(68.3M)(84.77M)(97.74M)(93.61M)
Operating Margin—————
Interest Income02.79M6.4M7.14M4.02M
Interest Expense00000
Other Income / Expenses(172K)2.9M6.21M7.14M4.01M
Income Before Tax(27.28M)(65.4M)(78.55M)(90.6M)(89.61M)
Pre-Tax Margin—————
Income Tax Expense03.71M73K(617K)49K
Net Income(27.28M)(69.1M)(78.63M)(89.98M)(89.66M)
Net Margin—————
EPS (Basic)(1.22)(4.42)(3.30)(2.85)(2.12)
EPS (Diluted)(1.22)(4.42)(3.30)(2.85)(2.12)
Weighted Avg Shares22.39M15.64M23.8M31.58M42.22M
Weighted Avg Shares (Diluted)22.39M15.64M23.8M31.58M42.22M

PepGen Inc.

NASDAQ:PEPG

Intrinsic Alpha fair value

Locked

Current Price

$3.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.